What's new on circulating tumor cells? A meeting report.
Standard
What's new on circulating tumor cells? A meeting report. / Lianidou, Evi S; Mavroudis, Dimitris; Sotiropoulou, Georgia; Agelaki, Sophia; Pantel, Klaus.
in: BREAST CANCER RES, Jahrgang 12, Nr. 4, 4, 2010, S. 307.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - What's new on circulating tumor cells? A meeting report.
AU - Lianidou, Evi S
AU - Mavroudis, Dimitris
AU - Sotiropoulou, Georgia
AU - Agelaki, Sophia
AU - Pantel, Klaus
PY - 2010
Y1 - 2010
N2 - Circulating tumor cells (CTCs) provide unique information for the management of cancer patients. The 7th International Symposium on Minimal Residual Cancer has focused on state of the art research, including exciting advances in understanding the biology of metastasis, CTCs and tumor dormancy. Particular emphasis was placed on the relationship of CTCs to cancer stem cells (CSCs) and the relevance of most recent findings for the development of new targeted therapies. CTCs were evaluated as promising tumor biomarkers and the design and results of the first clinical trials to determine their clinical utility were discussed together with state of the art technology platforms for CTC imaging, detection, quantification and molecular characterization. A liquid biopsy approach that can be used for prognostic and predictive purposes was proposed for the analysis of CTCs.
AB - Circulating tumor cells (CTCs) provide unique information for the management of cancer patients. The 7th International Symposium on Minimal Residual Cancer has focused on state of the art research, including exciting advances in understanding the biology of metastasis, CTCs and tumor dormancy. Particular emphasis was placed on the relationship of CTCs to cancer stem cells (CSCs) and the relevance of most recent findings for the development of new targeted therapies. CTCs were evaluated as promising tumor biomarkers and the design and results of the first clinical trials to determine their clinical utility were discussed together with state of the art technology platforms for CTC imaging, detection, quantification and molecular characterization. A liquid biopsy approach that can be used for prognostic and predictive purposes was proposed for the analysis of CTCs.
M3 - SCORING: Zeitschriftenaufsatz
VL - 12
SP - 307
JO - BREAST CANCER RES
JF - BREAST CANCER RES
SN - 1465-5411
IS - 4
M1 - 4
ER -
